2_Simple_Naive Profile Banner
TOO SIMPLE, SOMETIMES NAIVE. 懂了没啊? Profile
TOO SIMPLE, SOMETIMES NAIVE. 懂了没啊?

@2_Simple_Naive

Followers
106
Following
224
Statuses
43

MIKE WALLACE.

New York City
Joined January 2012
Don't wanna be here? Send us removal request.
@2_Simple_Naive
TOO SIMPLE, SOMETIMES NAIVE. 懂了没啊?
1 day
@coiniskingddd @longonlybio @drug_smolecules Yes PhD… hard to do this job without it. Cannot tell you how many MD investor miss the critical science questions because they are focused on the patients and data. I do not care if a drug shows good data, tell me its affinity
0
0
3
@2_Simple_Naive
TOO SIMPLE, SOMETIMES NAIVE. 懂了没啊?
1 day
@coiniskingddd @longonlybio @drug_smolecules Yes KOLs are often very informed... love to ask them the deep science questions they always have great insight
1
0
2
@2_Simple_Naive
TOO SIMPLE, SOMETIMES NAIVE. 懂了没啊?
1 day
@AaronRosenblum5 this looks just like they got lucky at week 14? week 12 delta is minimal/not viable and they got a very healthy population when you compare vs. historical placebo
1
0
0
@2_Simple_Naive
TOO SIMPLE, SOMETIMES NAIVE. 懂了没啊?
2 days
0
0
0
@2_Simple_Naive
TOO SIMPLE, SOMETIMES NAIVE. 懂了没啊?
2 days
@A_May_MD @coiniskingddd @Pharmdca This is more accurate GIF than you think… if you look at the rate of LGBT identification and semaglutide use over last 10 years they both going up… when Alex jones saying they are turning the frogs gay I believe that NVO and LLY are also using GLP-1 to turn America gay
1
0
1
@2_Simple_Naive
TOO SIMPLE, SOMETIMES NAIVE. 懂了没啊?
2 days
@coiniskingddd @A_May_MD @Pharmdca Market now knows that $VKTX has best in class obesity asset.... this chart looks like stock manipulation from big pharma $LLY and $NVO because they sense what's coming and want to stop it
1
0
4
@2_Simple_Naive
TOO SIMPLE, SOMETIMES NAIVE. 懂了没啊?
2 days
@BayAreaBiotechI @Sports_bios Probably not just from phlebotomy dont all these trials have freq blood draws? BPMC AE table would have listed anemia if it was frequent (2+ pts). The severity of THRD anemia is also a red flag and looks dose dependent.
0
0
0
@2_Simple_Naive
TOO SIMPLE, SOMETIMES NAIVE. 懂了没啊?
6 days
@Sanctuary_Bio lol jk in my dreams
0
0
0
@2_Simple_Naive
TOO SIMPLE, SOMETIMES NAIVE. 懂了没啊?
7 days
Tweet media one
1
1
23
@2_Simple_Naive
TOO SIMPLE, SOMETIMES NAIVE. 懂了没啊?
7 days
Tweet media one
0
0
16
@2_Simple_Naive
TOO SIMPLE, SOMETIMES NAIVE. 懂了没啊?
8 days
@A_May_MD Made for $KURA but also relevant here
Tweet media one
1
0
9
@2_Simple_Naive
TOO SIMPLE, SOMETIMES NAIVE. 懂了没啊?
8 days
Tweet media one
0
0
1
@2_Simple_Naive
TOO SIMPLE, SOMETIMES NAIVE. 懂了没啊?
8 days
@Pharmdca @FdetranaY you're right based on my diligence I think it will come back up. My PT is $200 based on large TAM
2
0
3
@2_Simple_Naive
TOO SIMPLE, SOMETIMES NAIVE. 懂了没啊?
9 days
@avidresearch lol $BBIO and $4-5b in sales pick one
0
0
0
@2_Simple_Naive
TOO SIMPLE, SOMETIMES NAIVE. 懂了没啊?
10 days
@Vulpescap @longonlybio How long are you going to wait for GHRS to get to market it doesn’t even have IND approved in the US still on hold
1
0
0
@2_Simple_Naive
TOO SIMPLE, SOMETIMES NAIVE. 懂了没啊?
20 days
@Sanctuary_Bio lol what just looking through s1 this looks 🗑️
1
0
2
@2_Simple_Naive
TOO SIMPLE, SOMETIMES NAIVE. 懂了没啊?
1 month
@adamfeuerstein Too messy, dose optimization a pain here. Yea maybe you can point to the cohorts that had better numbers and ignore the other ones but can you really believe it’s better or as good as CLDX?
1
0
2